{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicg7sud4tckxs336qqybwltjywpchy7znxlmzphphbqkxqcfm7yda",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mf5v4miu7yi2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihqfvc5cr33zwkxt225gysiczjth2vwdxmbia3ymg6aidyhxbecyy"
    },
    "mimeType": "image/jpeg",
    "size": 548357
  },
  "path": "/news/2026-02-docetaxel-rechallenge-linked-longer-survival.html",
  "publishedAt": "2026-02-18T14:20:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or switch to cabazitaxel when another taxane is needed? Findings from a new study published in JAMA Network Open give more insight into the question.",
  "title": "Docetaxel rechallenge linked to longer survival than cabazitaxel, study suggests"
}